MYCOLab Ai Logo - gold and army green

Postpartum depression: A role for psychedelics?

Summary

Postpartum depression affects many new mothers and involves feelings of disconnection from themselves and their babies. This review suggests that psilocybin, the active compound in psychedelic mushrooms, might help by promoting reconnection and acceptance. The authors examine safety data suggesting psilocybin could potentially be used safely in postpartum women if appropriate precautions are taken, such as temporarily stopping breastfeeding after treatment.

Background

Postpartum depression (PPD) is a major public health concern characterized by maternal disconnection from self, infant, and support systems. Current treatment modalities have low remission rates and emerging evidence for treatment resistance. PPD has distinct neurobiological features from major depressive disorder (MDD), particularly regarding the mother-infant relationship.

Objective

This narrative review outlines the potential therapeutic rationale for serotonergic psychedelics in treating PPD and highlights safety and pragmatic considerations for psychedelic use in the postpartum period. The authors examine evidence for PPD treatment and psychedelics in MDD, exploring safety considerations specific to the postpartum period.

Results

Evidence shows psilocybin has a favorable safety profile and catalyzes reconnection in MDD patients. Psilocybin demonstrates rapid antidepressant effects with sustained remission, promoting openness, acceptance, and connectedness. The review presents pharmacokinetic evidence suggesting psilocybin is largely eliminated within 48 hours, potentially allowing for safe use in breastfeeding with precautions.

Conclusion

Psychedelic-assisted therapy may address the core disconnection feature of PPD while improving maternal mood and maternal sensitivity toward infants. Given psilocybin’s safety profile in adults and MDD patients, pilot studies examining safety and efficacy in the postpartum period are warranted. Appropriate safety measures and inclusion of breastfeeding women could improve access to evidence-based treatments.
  • Published in:Journal of Psychopharmacology,
  • Study Type:Narrative Review,
  • Source: PMID: 35638179; DOI: 10.1177/02698811221093793
Scroll to Top